Candriam S.C.A. Purchases 131,623 Shares of Boston Scientific Corporation $BSX

Candriam S.C.A. grew its position in Boston Scientific Corporation (NYSE:BSX) by 11.6% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,261,461 shares of the medical equipment provider’s stock after purchasing an additional 131,623 shares during the period. Candriam S.C.A.’s holdings in Boston Scientific were worth $79,157,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the company. Outfitters Financial LLC grew its position in Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares in the last quarter. Fayez Sarofim & Co lifted its position in shares of Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after buying an additional 111 shares in the last quarter. Natural Investments LLC boosted its stake in shares of Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after buying an additional 112 shares during the last quarter. Old Port Advisors grew its holdings in shares of Boston Scientific by 4.7% in the fourth quarter. Old Port Advisors now owns 2,558 shares of the medical equipment provider’s stock valued at $244,000 after acquiring an additional 115 shares in the last quarter. Finally, Thrive Wealth Management LLC grew its holdings in shares of Boston Scientific by 1.6% in the fourth quarter. Thrive Wealth Management LLC now owns 7,387 shares of the medical equipment provider’s stock valued at $704,000 after acquiring an additional 117 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

Boston Scientific stock opened at $44.67 on Friday. The business’s 50 day simple moving average is $49.41 and its 200 day simple moving average is $67.70. Boston Scientific Corporation has a 12 month low of $42.25 and a 12 month high of $109.50. The company has a market cap of $66.40 billion, a price-to-earnings ratio of 18.69, a PEG ratio of 0.86 and a beta of 0.58. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the business posted $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Piper Sandler restated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Stifel Nicolaus lowered their target price on Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Bank of America cut their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Citigroup reduced their price target on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $81.32.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 9,800 shares of company stock worth $554,012. Company insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.